Literature DB >> 14993418

Targeting the FLICE Inhibitory Protein (FLIP) in cancer therapy.

Harald Wajant1.   

Abstract

In some cases, treatment of ovarian cancer cells with tumor necrosis factor-alpha can induce an apoptotic signal leading to the death of these cells; however, many ovarian malignancies are resistant to the effects of TNF-alpha. A new publication describes how these ovarian tumors may evade death receptor-mediated apoptosis. Apparently, the extracellular signals transduced by death receptors (e.g., TNF receptors) are extinguished before the cascade of caspases, which proteolytically cleave other proteins, can be activated. Overexpression of FLIP, a protein that blocks the caspase activity of FLICE, mediates the observed resistance. Thus, FLIP, which normally prevents inappropriate apoptosis, may become a tumor progression factor. Strategies to overcome this FLIP-mediated blockade of programmed cell death in tumors might become useful for positive prognoses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14993418     DOI: 10.1124/mi.3.3.124

Source DB:  PubMed          Journal:  Mol Interv        ISSN: 1534-0384


  28 in total

1.  S-nitrosylation of FLICE inhibitory protein determines its interaction with RIP1 and activation of NF-κB.

Authors:  Siera Jo Talbott; Sudjit Luanpitpong; Christian Stehlik; Neelam Azad; Anand Krishnan V Iyer; Liying Wang; Yon Rojanasakul
Journal:  Cell Cycle       Date:  2014-04-24       Impact factor: 4.534

2.  The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation.

Authors:  Songqing Fan; Yikun Li; Ping Yue; Fadlo R Khuri; Shi-Yong Sun
Journal:  Neoplasia       Date:  2010-04       Impact factor: 5.715

3.  The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition.

Authors:  Bo Li; Hui Ren; Ping Yue; Mingwei Chen; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Prev Res (Phila)       Date:  2012-02-16

4.  Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3.

Authors:  Shuzhen Chen; Wei Cao; Ping Yue; Chunhai Hao; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2011-08-25       Impact factor: 12.701

5.  Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.

Authors:  Imtiyaz Murtaza; Mohammad Saleem; Vaqar Mustafa Adhami; Bilal Bin Hafeez; Hasan Mukhtar
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

6.  Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3'-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein.

Authors:  Yabing Chen; Jianmin Xu; Nirag Jhala; Pritish Pawar; Zeng B Zhu; Liping Ma; Chang-Hyun Byon; Jay M McDonald
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

7.  Endogenous hydrogen peroxide regulates glutathione redox via nuclear factor erythroid 2-related factor 2 downstream of phosphatidylinositol 3-kinase during muscle differentiation.

Authors:  Yan Ding; Kyu Jin Choi; Jin Hwan Kim; Xuezhe Han; Yuji Piao; Jin-Hyun Jeong; Wonchae Choe; Insug Kang; Joohun Ha; Henry Jay Forman; Jinhwa Lee; Kyung-Sik Yoon; Sung Soo Kim
Journal:  Am J Pathol       Date:  2008-05-05       Impact factor: 4.307

8.  c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.

Authors:  John Kauh; Songqing Fan; Mingjing Xia; Ping Yue; Lily Yang; Fadlo R Khuri; Shi-Yong Sun
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

9.  mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis.

Authors:  Liqun Zhao; Ping Yue; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2013-01-14       Impact factor: 12.701

Review 10.  FLIP as an anti-cancer therapeutic target.

Authors:  Jin Kuk Yang
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.